{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Wong BS"],"funding":["U.S. Department of Health & Human Services | NIH | National Cancer Institute","A.Q.H. was also supported by the Mayo Clinic Clinician Investigator Award and the William J. and Charles H. Mayo Professorship","U.S. Department of Defense","NCI NIH HHS"],"pagination":["26-40"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC7855796"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["5(1)"],"pubmed_abstract":["Clinical scores, molecular markers and cellular phenotypes have been used to predict the clinical outcomes of patients with glioblastoma. However, their clinical use has been hampered by confounders such as patient co-morbidities, by the tumoral heterogeneity of molecular and cellular markers, and by the complexity and cost of high-throughput single-cell analysis. Here, we show that a microfluidic assay for the quantification of cell migration and proliferation can categorize patients with glioblastoma according to progression-free survival. We quantified with a composite score the ability of primary glioblastoma cells to proliferate (via the protein biomarker Ki-67) and to squeeze through microfluidic channels, mimicking aspects of the tight perivascular conduits and white-matter tracts i"],"journal":["Nature biomedical engineering"],"pubmed_title":["A microfluidic cell-migration assay for the prediction of progression-free survival and recurrence time of patients with glioblastoma."],"pmcid":["PMC7855796"],"funding_grant_id":["R01-CA183804","R01 CA183804","R01-CA124704","R01-CA216855","CA160997","R01 CA216855","R01 CA124704"],"pubmed_authors":["Shah SR","ReFaey K","Zheng X","Wong BS","Wu PH","Schiapparelli P","Fan CM","Ifemembi B","Konstantopoulos K","Chin D","Yankaskas CL","Bajpai VK","Martin SS","Quinones-Hinojosa A"],"additional_accession":[]},"is_claimable":false,"name":"A microfluidic cell-migration assay for the prediction of progression-free survival and recurrence time of patients with glioblastoma.","description":"Clinical scores, molecular markers and cellular phenotypes have been used to predict the clinical outcomes of patients with glioblastoma. However, their clinical use has been hampered by confounders such as patient co-morbidities, by the tumoral heterogeneity of molecular and cellular markers, and by the complexity and cost of high-throughput single-cell analysis. Here, we show that a microfluidic assay for the quantification of cell migration and proliferation can categorize patients with glioblastoma according to progression-free survival. We quantified with a composite score the ability of primary glioblastoma cells to proliferate (via the protein biomarker Ki-67) and to squeeze through microfluidic channels, mimicking aspects of the tight perivascular conduits and white-matter tracts i","dates":{"release":"2021-01-01T00:00:00Z","publication":"2021 Jan","modification":"2026-05-09T01:18:36.24Z","creation":"2022-02-09T08:14:47.769Z"},"accession":"S-EPMC7855796","cross_references":{"pubmed":["32989283"],"doi":["10.1038/s41551-020-00621-9"]}}